Drug Alert: 27 drug samples fail to clear CDSCO test, 1 declared spurious
In its latest drug safety alert, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has flagged 27 medicine batches for failing to qualify for a random drug sample test for the month of May– 2023, while one drug sample has been declared Spurious.
These drug samples which are declared not of standard quality include Jackson Laboratories' Bupivacaine Heavy (Bupivacaine Hydrochloride in Dextrose Injection USP 4 ml), Alves Healthcare's Doxycycline Capsules IP, Terrace Pharmaceuticals' Teripil -80 (Telmisartan Tablets I.P.), Bengal Chemical and Pharmaceuticals' Ofloxacin and Ornidazole Tablets IP, Zee Laboratories' MONAMOX-CL 625 (Amoxycillin& Potassium Clavulanate Tablets I.P.) and others.
For more details, check out the full story on the link below:
CDSCO Drug Alert: 27 Drug Samples Flagged
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.